Shorter TB treatment could help kidney transplant patients get safer surgery
NCT ID NCT05411744
First seen Jan 24, 2026 · Last updated Apr 25, 2026 · Updated 12 times
Summary
This study tests a one-month course of three medicines (isoniazid, rifapentine, and vitamin B6) for latent tuberculosis in 25 adults with end-stage kidney disease who are candidates for a kidney transplant. The goal is to see if the short treatment is safe and if patients can complete it. Latent TB is a dormant infection that could become active after transplant, so treating it beforehand may reduce risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pinki J Bhatt
New Brunswick, New Jersey, 08901, United States
Conditions
Explore the condition pages connected to this study.